Expert Insights

Shannon N. Westin, MD, of The University of Texas MD Anderson Cancer Center in Houston, discusses findings from the second interim overall survival analysis of the phase 3 DUO-E/GOG-3041/ENGOT-EN10 trial, presented at the 2026 ESMO Congress...

Eleftherios P. Mamounas, MD, MPH, FACS, discusses the final 15-year analysis of the phase 3 NRG Oncology/NSABP B-42 trial, presented at the 2026 ESMO Congress. The randomized, double-blind, placebo-controlled study evaluated whether 5...

Nikhil I. Khushalani, MD, discusses the primary analysis of the phase 3 HBI-8000-303 trial, presented at the 2026 ESMO Congress in Madrid, Spain. The global, randomized study evaluated HBI-8000, an oral selective histone deacetylase (HDAC)...

Jacob Sands, MD, discusses the primary analysis of the phase 3 DeLLphi-305 trial, presented at the 2026 European Society for Medical Oncology (ESMO) Congress.

Sara Hurvitz, MD, discusses final results from TALENT, a phase 2 investigator-initiated neoadjuvant trial presented at the 2026 European Society for Medical Oncology (ESMO) Congress.

Benjamin Garmazy, MD, discusses phase 1 results evaluating the first-in-class androgen receptor–targeted RIPTAC JNJ-6143 in heavily pretreated metastatic castration-resistant prostate cancer, highlighting encouraging PSA responses across...

Nilofer Azad, MD, discusses results from a randomized phase 3 trial evaluating tovecimig plus paclitaxel versus paclitaxel alone in previously treated advanced biliary tract cancer, highlighting improved response rates and progression-free...

Matteo Carlino, MD, discusses results from the phase 3 INTerpath-001 trial evaluating personalized neoantigen therapy with intismeran autogene plus pembrolizumab in resected melanoma, highlighting improved recurrence-free and distant...

Jaafar Bennouna, MD, PhD, discusses results from the phase 3 IROCAS trial comparing adjuvant mFOLFIRINOX with mFOLFOX6 in patients with resected high-risk stage III colon cancer, highlighting the absence of disease-free survival improvement,...

Daniel Heng, MD, discusses updated results from the LITESPARK-011 trial evaluating belzutifan plus lenvatinib versus cabozantinib in advanced renal cell carcinoma, highlighting improved progression-free survival, higher response rates,...